Completed Cancer Diabetes, Hormones & Metabolism
Development of a multi-peptide immunotherapeutic for Type 1 diabetes to first-in-human stage (MultipPepT1De)
About this grant
This summary is based on the grant title only — the full abstract was not available.
Research project funded by Wellcome at King's College London.
View the original record at the funder ↗
Researchers
Mark Peakman (EPMC Awardee)
Related Research
Grants with similar aims, by meaning.
Epitope selection for peptide immunotherapy of Type 1 diabetes in man using a humanised mouse model of diabetes
Defining peptide epitopes of islet antigens for detailed characterisation and immunotherapy of Type 1 diabetes
Developing a pre-clinical human pancreatic cancer model to test novel immunotherapies.
MELD-ATG: Phase II, dose ranging, efficacy study of anti-thymocyte globulin (ATG) within 6 weeks of diagnosis of type 1diabetes (T1D)
Preclinical in vivo assessment of a combination of protein and cell therapies to prevent human islet transplant rejection as a cure for Type 1 diabete
Original classification
Translation AwardPlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know